COMMUNIQUÉS West-GlobeNewswire

Verano Announces Strong Third Quarter 2026 Financial Results Highlighted by $212 Million in Revenue and Year-Over-Year Organic Growth
29/10/2026
Company generates revenue increase of $10 million, or 5%, and highest level of cash flow from operations in four years CHICAGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“ [...]
Ligand Reports Third Quarter 2026 Financial Results
29/10/2026
Third-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50 1 ; Reaffirms Revenue Guidance Conference call begins at 8: [...]
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
29/10/2026
DEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead Stage WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage [...]
BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
29/10/2026
—New data highlight BioCryst's commitment to advancing a portfolio of therapies for people living with HAE— RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) [...]
Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance
29/10/2026
Company estimates approximately one million U.S. patients each month discontinue GLP-1 medications and face the risk of weight regain One-third of surveyed GLP-1 users expressed a preference for an endoscopic procedure [...]
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
29/10/2026
24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Supplemental Biologics [...]
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
29/10/2026
Over 2 million total VOQUEZNA® prescriptions filled through October 16, 2026 Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026 Generated positive operating cash flow for the second [...]
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29/10/2026
FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis [...]
Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
29/10/2026
Appointments strengthen scientific leadership and operational capabilities as Opus advances its pipeline of gene therapies for inherited retinal diseases RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- [...]
Tilray Brands Announces Next Phase of Beverage Transformation
29/10/2026
Successfully Completed Consolidation of U.S. Brewing Footprint from 10 Facilities to Six Identifying Further Opportunities to Reduce Complexity, Improve Brewery Utilization and Strengthen Margins Transformation [...]
Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences
29/10/2026
BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation [...]
Novastra Therapeutics to Present First-in-Human Data for OAP-101 in Checkpoint-Refractory Advanced Melanoma at SITC 2026 Annual Meeting
29/10/2026
Feasibility and innate-to-Th1 pharmacodynamics for candidate OAP-101, built on proprietary OmniAntigen™ Platform (OAP) OAP enables systematic immune reprogramming therapy (XIRT™) to overcome resistance of cold solid [...]
Sironax Announces Three Abstracts on SARM1 Inhibitor SIR2501 Selected for Presentation at Neuroscience 2026
29/10/2026
Society for Neuroscience Annual Meeting, November 14-18, Washington, DC WALTHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company developing transformative therapies for [...]
Indivior Reports Third Quarter 2026 Financial Results
29/10/2026
Q3’26 Total Net Revenue of $ 356 Million, Up 13% YoY Record Quarterly Total SUBLOCADE® Net Revenue of $ 267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $ 137 Million and Record Non-GAAP Net Income of $ [...]
Coloplast opens new factory in Portugal to support global growth
29/10/2026
Coloplast today inaugurates its largest manufacturing site to date, a two-floor 50,000 m2 facility in Felgueiras, Portugal, expanding the company’s production capacity to meet growing global demand for continence care [...]
TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd.
29/10/2026
TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd. TME Pharma receives €150,000 for 6 months of exclusivity to negotiate a definitive agreement for worldwide rights to NOX-A12 TMS Co., [...]
TME Pharma signe un accord de négociation exclusif et contraignant avec la société japonaise TMS Co., Ltd.
29/10/2026
TME Pharma signe un accord de négociation exclusif et contraignant avec la société japonaise TMS Co., Ltd. TME Pharma TME Pharma reçoit 150 000 € en échange de 6 mois d’exclusivité pour négocier un accord définitif [...]
Vistin Pharma ASA (VISTN): Key information relating to the cash dividend
29/10/2026
The Board of Directors has resolved to pay an additional ordinary cash dividend of NOK 0.50 per share in November, pursuant to the authorization granted by the Annual General Meeting on 20 May 2026. Dividend amount (per [...]
Vistin Pharma ASA: Third quarter and YTD 2026 financial results
29/10/2026
Vistin Pharma ASA: Third quarter and YTD 2026 financial results Oslo, Norway, 29 October 2026 Vistin Pharma ASA (VISTN) today announces its financial results for the third quarter and year to date 2026. Revenue in the [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum